HMGCR and breast cancer: We have shown that in the presence of an exogenous supply of cholesterol and fatty acids, inhibition of HMGCR activity with atorvastatin triggers a progressive dose-dependent accumulation of neutral lipids specifically in the BC cells displaying little or no anti-proliferative response to the treatment (resistance).